Dermatological Drugs Market Forecast 2014-2024

Future Prospects for Leading Companies

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of visiongain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each purchase and single copy is for personal use only.

www.visiongain.com

Contents

1. Executive Summary

1.1 Overview of Findings

1.2 Structure of the Report

1.3 Research and Analysis Methods

1.4 Scope of this Report

1.5 Glossary of Terms in this Report

2. Introduction to Dermatological Drugs

2.1 The Pharmaceutical Industry: a Very Brief Overview

2.2 An Overview of Dermatology

2.2.1 The Structure of the Skin, Hair and Nails

2.2.2 Hair and Nails

2.2.3 Sweat and Sebaceous Glands

2.2.4 Functions of the Skin

2.3 Common Skin Diseases

2.4 Acne: The Most Common Skin Disease

2.4.1 Acne: Epidemiology

2.4.2 Acne: Causes and Pathogenesis

2.4.3 Acne: Treatment

2.5 Dermatitis: Inflammation of the Skin

2.5.1 Atopic Dermatitis

2.5.2 Contact Dermatitis

2.5.3 Seborrhoeic Dermatitis

1. Executive Summary

2. Introduction to Dermatological Drugs

www.visiongain.com

Contents

2.5.4 Nummular Dermatitis

2.5.5 Perioral Dermatitis

2.6 Psoriasis: A Complex Multi-factorial Disease

2.7 Rosacea: Vascular Instability

2.8 Alopecia: Excessive Shedding of Hair

2.9 Skin Infections: A Serious Healthcare Threat

2.9.1 Bacterial Skin Infections

2.9.2 Fungal Skin Infections

2.9.3 Viral Skin Infections

2.10 Common Skin Treatments

2.10.1 Creams and Semisolid Emulsions

2.10.2 Ointments

2.10.3 Lotions

2.10.4 Solutions

2.10.5 Occlusive Therapy

2.10.6 Cleansing Agents

2.10.7 Powders and Hydrophilic Polymer

2.10.8 Anti-Infective Agents

2.10.9 Anti-Inflammatory Agents

2.11 Phases of Clinical Trials

2.12 Dermatological Drugs in This Report

3. Dermatological Drugs: World Market 2014-2024

3.1 The World Dermatological Drugs Market in 2012 and 2013

3. Dermatological Drugs: World Market 2014-2024

www.visiongain.com

Contents

3.1.1 Leading Dermatological Drugs

3.1.2 Leading Companies in the Dermatological Drugs Market

3.2 World Dermatological Drugs Market: Sales Forecast 2014-2024

3.3 Psoriasis Drugs Lead the World Dermatological Drugs Market

3.4 How Will Segmental Market Shares Change to 2024?

3.5 World Dermatological Drugs Market: Drivers and Restraints 2014-2024

3.6 Opportunities for Blockbuster Sales

4. Leading National Markets 2014-2024

4.1 Geographical Breakdown of the World Dermatological Drugs Market

4.2 World Dermatological Drugs Market: National Markets Forecast 2014-2024

4.2.1 How Will National Market Shares Change to 2024?

4.3 The US Dermatological Drugs Market 2014-2024

4.3.1 US Dermatological Drugs Market Forecast 2014-2024

4.3.2 US Dermatological Drugs Market: Trends and Developments

4.3.2.1 Affordable Care Act: Expanding Medicare Coverage

4.3.2.2 A US Biosimilars Market?

4.4 Japanese Dermatological Drugs Market 2014-2024

4.4.1 Japanese Dermatological Drugs Market Forecast 2014-2024

4.4.2 Japanese Dermatological Drugs Market: Trends and Developments

4.4.2.1 The Cost of Treatment in Japan

4.4.2.2 Japanese Pharmaceutical Industry Regulatory Reform

4.5 Chinese Dermatological Drugs Market 2014-2024

4.5.1 Chinese Dermatological Drugs Market Forecast 2014-2024

4. Leading National Markets 2014-2024

www.visiongain.com

Contents

4.5.2 Chinese Dermatological Drugs Market: Trends and Developments

4.5.2.1 Expansion of Healthcare Coverage and Reimbursement

4.5.2.2 Rapid Advancement of Dermatology in China

4.5.2.3 Price Controls and the Anhui Model

4.6 EU5 Dermatological Drugs Market 2014-2024

4.6.1 German Dermatological Drugs Market Forecast 2014-2024

4.6.2 French Dermatological Drugs Market Forecast 2014-2024

4.6.3 UK Dermatological Drugs Market Forecast 2014-2024

4.6.4 Italian Dermatological Drugs Market Forecast 2014-2024

4.6.5 Spanish Dermatological Drugs Market Forecast 2014-2024

4.7 Indian Dermatological Drugs Market 2014-2024

4.7.1 Indian Dermatological Drugs Market Forecast 2014-2024

4.7.2 Indian Dermatological Drugs Market: Trends and Developments

4.7.2.1 Drug Prices Control Order 2013

4.7.2.2 Expansion of Healthcare Provision

4.8 Brazilian Dermatological Drugs Market 2014-2024

4.8.1 Brazilian Dermatological Drugs Market Forecast 2014-2024

4.8.2 Brazilian Dermatological Drugs Market: Trends and Developments

4.8.2.1 Increasing Access to Medicines

4.9 Russian Dermatological Drugs Market 2014-2024

4.9.1 Russian Dermatological Drugs Market Forecast 2014-2024

4.9.2 Russian Dermatological Drugs Market: Trends and Developments

4.9.2.1 Pharma2020, Healthcare and Industry Reform

4.10 Mexican Dermatological Drugs Market 2014-2024

www.visiongain.com

Contents

4.10.1 Mexican Dermatological Drugs Market Forecast 2014-2024

4.10.2 Mexican Dermatological Drugs Market: Trends and Developments

4.10.2.1 Seguro Popular: Mexican Healthcare Reform

4.10.2.2 International Interest in Mexico

5. Psoriasis Drugs Market 2014-2024

5.1 Drugs for Psoriasis: The Success of Biologics

5.2 Leading Products in the Psoriasis Drug Market in 2012 and 2013

5.3 Psoriasis Drugs: Trends and Developments

5.3.1 Biological Drugs: An Overview

5.3.1.1 Disadvantages of Biologics

5.4 Psoriasis Drugs: Market Forecast 2014-2024

5.5 Market Share of Leading Psoriasis Drugs to 2024

5.6 Humira (adalimumab, AbbVie)

5.6.1 Humira: Sales Forecast 2014-2024

5.6.2 Prospects for Biosimilar Humira

5.7 Enbrel (etanercept, Amgen/Pfizer)

5.7.1 Enbrel: Sales Forecast 2014-2024

5.7.2 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years

5.7.3 Competition from Other Drugs

5.7.4 Biosimilar Competition for Enbrel

5.8 Stelara (ustekinumab, Johnson & Johnson)

5.8.1 Stelara: Sales Forecast 2014-2024

5.8.2 Competition for Stelara in the Pipeline

5. Psoriasis Drugs Market 2014-2024

www.visiongain.com

Contents

5.9 Remicade (infliximab, Johnson & Johnson)

5.9.1 Remicade: Sales Forecast 2014-2024

5.10 Daivobet (betamethasone/calcipotriene, LEO Pharma)

5.10.1 Daivobet: Sales Forecast 2014-2024

5.10.2 LEO Pharma’s Life Cycle Management of Daivobet

5.10.3 Daivobet/Dovobet/Taclonex – Generic Competition

5.11 Soriatane (acitretin, GSK)

5.11.1 Soriatane: Sales Forecast 2014-2024

5.12 Psoriasis Drugs Market: Summary

6. Skin Infection Drugs Market 2014-2024

6.1 Skin Infection Drugs: A Growing Submarket

6.2 Leading Products in the Skin Infections Drug Market in 2012 and 2013

6.3 Skin Infection Drugs: Market Forecast 2014-2024

6.4 Market Share of Leading Skin Infection Drugs to 2024

6.5 Cubicin (daptomycin, Cubist Pharmaceuticals)

6.5.1 Cubicin: Sales Forecast 2014-2024

6.5.2 Cubicin Lifecycle Management Strategies

6.5.3 Generic Competition for Cubicin

6.6 Zyvox (linezolid, Pfizer)

6.6.1 Zyvox: Sales Forecast 2014-2024

6.6.2 Tedizolid Threatens Zyvox Market Share

6.7 Valtrex (valaciclovir, GSK)

6.7.1 Valtrex: Sales Forecast 2014-2024

6. Skin Infection Drugs Market 2014-2024

www.visiongain.com

Contents

6.8 Canesten (clotrimazole, Bayer)

6.8.1 Canesten: Sales Forecast 2014-2024

6.9 Zovirax (aciclovir, Valeant/GSK)

6.9.1 Zovirax: Sales Forecast 2014-2024

6.9.2 Valeant Acquires Zovirax in US and Canada

6.9.3 Mylan’s Generic Zovirax and Actavis’s Authorised Generic

6.10 Bactroban (mupirocin, GSK)

6.10.1 Bactroban: Sales Forecast 2014-2024

6.11 Lamisil (terbinafine, Novartis)

6.11.1 Lamisil: Sales Forecast 2014-2024

6.11.2 Lamisil Sales Affected by Novartis Manufacturing Problems

6.12 Skin Infection Drugs Market: Summary

7. Acne Drugs Market 2014-2024

7.1 Drugs for Acne: A Highly Fragmented Market

7.2 Leading Products in the Acne Drug Market in 2012 and 2013

7.3 Acne Drugs: Trends and Developments

7.3.1 Combination Treatments for Acne

7.3.2 Oral Contraceptives in Treating Acne

7.3.3 Generic Competition in the Acne Drugs Market

7.4 Acne Drugs: Market Forecast 2014-2024

7.5 Market Share of Leading Acne Drugs to 2024

7.6 Solodyn (minocycline, Valeant)

7.6.1 Solodyn: Sales Forecast 2014-2024

7. Acne Drugs Market 2014-2024

www.visiongain.com

Contents

7.6.2 Antitrust Action over Solodyn Pay-For-Delay Deals

7.6.3 Impax and Medicis Collaborating on Advanced Solodyn

7.6.4 Medicis and Lupin Settle

7.7 Claravis (isotretinoin, Teva)

7.7.1 Claravis: Sales Forecast 2014-2024

7.8 Epiduo (adapalene/benzoyl peroxide, Galderma)

7.8.1 Epiduo: Sales Forecast 2014-2024

7.8.2 Galderma and Par Pharmaceutical Settle over Generic Epiduo

7.8.3 Epiduo Approved for Patients Aged 9-11 Years

7.9 Differin (adapalene, Galderma)

7.9.1 Differin: Sales Forecast 2014-2024

7.9.2 Federal Circuit Court Invalidates Differin Patents

7.10 Duac (clindamycin/benzoyl peroxide, GSK)

7.10.1 Duac: Sales Forecast 2014-2024

7.11 Aczone (dapsone, Allergan)

7.11.1 Aczone: Sales Forecast 2014-2024

7.12 Amnesteem (isotretinoin, Mylan)

7.12.1 Amnesteem: Sales Forecast 2014-2024

7.13 Doryx (doxycycline, Actavis)

7.13.1 Doryx: Sales Forecast 2014-2024

7.13.2 Warner Chilcott’s Lifecycle Management Strategies

7.13.3 Generic Competition for Doryx

7.14 Ziana (clindamycin/tretinoin, Valeant)

7.14.1 Ziana: Sales Forecast 2014-2024

www.visiongain.com

Contents

7.14.2 Actavis to Launch Generic Ziana in 2016

7.15 Acanya (clindamycin/benzoyl peroxide, Dow/Valeant)

7.15.1 Acanya: Sales Forecast 2014-2024

7.15.2 Actavis Claims First-to-File Exclusivity for its Acanya ANDA

7.15.3 Dow/Valeant File Suit Against Perrigo’s ANDA

7.16 Absorica/Epuris (CIP-isotretinoin, Cipher)

7.16.1 Absorica/Epuris: Sales Forecast 2014-2024

7.17 Other Products

7.17.1 Diane (cyproterone/ethinyl estradiol, Bayer)

7.17.2 Veltin (tretinoin/clindamycin, GSK)

7.18 Acne Drugs Market: Summary

8. Dermatitis Drugs Market 2014-2024

8.1 Dermatitis Drugs: High Generic Penetration

8.2 Leading Products in the Dermatitis Drug Market in 2012 and 2013

8.3 Dermatitis Drugs: Market Forecast 2014-2024

8.4 Market Share of Leading Dermatitis Drugs to 2024

8.5 Bepanthen (dexpanthenol, Bayer)

8.5.1 Bepanthen: Sales Forecast 2014-2024

8.6 Protopic (tacrolimus, Astellas Pharma/Roche)

8.6.1 Protopic: Sales Forecast 2014-2024

8.6.2 Protopic Benefits from Expanded Indication

8.6.3 Generic Competition for Protopic

8.7 Elocon (mometasone, Merck & Co.)

8. Dermatitis Drugs Market 2014-2024

www.visiongain.com

Contents

8.7.1 Elocon: Sales Forecast 2014-2024

8.8 Elidel (pimecrolimus, Meda/Valeant)

8.8.1 Elidel: Sales Forecast 2014-2024

8.9 Dermatitis Drugs Market: Summary

9. Leading Companies in the Dermatological Drugs Market

9.1 Galderma

9.1.1 Galderma: Dermatological Drugs Product Portfolio

9.1.2 Galderma: Sales Forecast 2014-2024

9.1.3 Galderma: Products in Development

9.1.3.1 NVC-422 (auriclosene) for Rosacea

9.1.4 Galderma: Recent Developments

9.1.4.1 Nestlé Acquires 100% of Galderma

9.1.4.2 Galderma Laboratories Restructuring

9.1.4.3 Mirvaso Launched for Rosacea

9.2 Johnson & Johnson

9.2.1 Johnson & Johnson: Dermatological Drugs Product Portfolio

9.2.2 Johnson & Johnson: Sales Forecast 2014-2024

9.2.3 Johnson & Johnson: Products in Development

9.3 AbbVie

9.3.1 AbbVie: Dermatological Drugs Product Portfolio

9.3.2 AbbVie: Sales Forecast 2014-2024

9.3.3 AbbVie: Products in Development

9.3.3.1 BT-061 (tregalizumab) for Psoriasis

9. Leading Companies in the Dermatological Drugs Market

www.visiongain.com

Contents

9.4 GSK

9.4.1 GSK: Dermatological Drugs Product Portfolio

9.4.2 GSK: Sales Forecast 2014-2024

9.4.3 GSK: Products in Development

9.4.4 GSK: Recent Developments

9.4.4.1 Tafinlar and Mekinist Combination Approved by FDA, Withdrawn in EU

9.4.4.2 GSK’s China Corruption Probe

9.5 Pfizer

9.5.1 Pfizer: Dermatological Drugs Product Portfolio

9.5.2 Pfizer: Sales Forecast 2014-2024

9.5.3 Pfizer: Products in Development

9.6 LEO Pharma

9.6.1 LEO Pharma: Dermatological Drugs Product Portfolio

9.6.2 LEO Pharma: Sales Forecast 2014-2024

9.6.3 LEO Pharma: Products in Development

10. Dermatological Drugs Pipeline Analysis 2014-2024

10.1 New Technology in R&D Pipeline Activities

10.1.1 Reformulation

10.1.2 Combination Treatments

10.1.3 New Mechanisms and Drug Delivery Technologies

10.1.4 Potential Market Entrants

10.2 Psoriasis: Filed or Recently Launched

10.2.1 Cimzia (certolizumab, UCB)

10. Dermatological Drugs Pipeline Analysis 2014-2024

www.visiongain.com

Contents

10.2.2 Sorilux (calcipotriene foam, GSK)

10.3 Psoriasis: Phase 3 Pipeline

10.3.1 000-0551 Lotion (halobetasol, Therapeutics, Inc.)

10.3.2 AIN457 (secukinumab, Novartis)

10.3.3 AMG827 (brodalumab, AstraZeneca/Amgen)

10.3.4 CF101 (IB-MECA, Can-Fite BioPharma)

10.3.5 LAS41008 (dimethyl fumarate , Almirall)

10.3.6 LEO 90100 (LEO Pharma)

10.3.7 LY2439821 (ixekizumab, Eli Lilly)

10.3.8 MK-3222/SCH 900222 (tildrakizumab, Merck)

10.3.9 Otezla (apremilast, Celgene)

10.3.10 STF 115469 (calcipotriene foam, GSK)

10.3.11 Xeljanz (tofacitinib, Pfizer)

10.4 Psoriasis: Phase 2 Pipeline

10.4.1 AN2728 (PDE-4 inhibitor, Anacor Pharmaceuticals)

10.4.2 CNTO 1959 (guselkumab, MorphoSys/Janssen)

10.4.3 CT327 (TrkA inhibitor, Creabilis Therapeutics)

10.4.4 ASP015K (JAK inhibitor, Janssen/Astellas)

10.4.5 Jakavi/Jakafi (ruxolitinib, Incyte/Novartis)

10.4.6 LY3009104 (baricitinib, Incyte/Eli Lilly)

10.4.7 PH-10 (Rose bengal, Provectus Biopharmaceuticals)

10.5 Psoriasis: Phase 1 and Preclinical Pipeline

10.6 Psoriasis: Recently Terminated Drugs

10.6.1 Ozespa (briakinumab, Abbott)

www.visiongain.com

Contents

10.6.2 AEB071 (sotrastaurin, Novartis)

10.6.3 Voclera (voclosporin, Aurinia)

10.7 Skin Infections: Phase 3 Pipeline

10.7.1 AN2690 (tavaborole, Anacor)

10.7.2 Dalvance (dalbavancin, Durata Therapeutics)

10.7.3 Delafloxacin (delafloxacin, Melinta Pharmaceuticals)

10.7.4 Jublia (efinaconazole, Valeant)

10.7.5 NB-001 (NanoBio Corporation)

10.7.6 Nuvocid (oritavancin, The Medicines Company)

10.7.7 TR-701 (tedizolid, Cubist)

10.7.8 Luliconazole (Topica Pharmaceuticals)

10.8 Skin Infections: Phase 2 Pipeline

10.9 Skin Infections: Phase 1 and Preclinical Pipeline

10.10 Acne: Phase 3 Pipeline

10.10.1 Duac low dose (clindamycin/benzoyl peroxide, GSK)

10.10.2 Visonac (photodynamic therapy, Photocure)

10.11 Acne: Phase 2 Pipeline

10.12 Acne: Phase 1 and Preclinical Pipeline

10.12.1 Acne Vaccine – A Treatment for the Future?

10.13 Dermatitis: Phase 3 Pipeline

10.13.1 Toctino (alitretinoin, GSK)

10.13.2 Dermadexin and Pruridexin (P3CGM, Astion Pharma)

10.13.3 Dexeryl Cream (glycerol/paraffin emollient, Pierre Fabre)

10.13.4 Soriatane (acitretin, InnovaDerm/Tribute Pharmaceuticals)

www.visiongain.com

Contents

10.14 Dermatitis: Phase 2 Pipeline

10.14.1 REGN668/SAR231893 (dupilumab, Regeneron/Sanofi)

10.15 Dermatitis: Phase 1 and Preclinical Pipeline

10.16 Other Dermatological Drugs: Filed or Recently Launched

10.16.1 Actikerall (fluorouracil/salicylic acid, Almirall)

10.16.2 Ameluz (5-ALA photodynamic therapy, Biofrontera)

10.16.3 Mirvaso (brimonidine, Galderma)

10.16.4 Picato (ingenol mebutate, LEO Pharma)

10.16.5 Xolair (omalizumab, Novartis/Roche)

10.17 Other Dermatological Drugs: Phase 3 Pipeline

10.17.1 Atralin (tretinoin, Valeant)

10.17.2 BMS-936558 (nivolumab, Bristol-Myers Squibb)

10.17.3 CD5024 (ivermectin, Galderma)

10.17.4 Latisse (bimatoprost, Allergan)

10.17.5 LEE011, LGX818 and MEK162 (Novartis)

10.17.6 MK-3475 (lambrolizumab, Merck)

10.17.7 Oleogel-S10 (triterpene extract, Birken)

10.17.8 PV-10 (Rose bengal, Provectus Pharmaceuticals)

10.17.9 SR-T100 gel (Solanum incanum extract, G&E Herbal Biotechnology)

10.17.10 TVEC (talimogene laherparepvec, Amgen)

10.18 Other Dermatological Drugs: Phase 2 Pipeline

10.19 Other Dermatological Drugs: Phase 1 and Preclinical Pipeline

www.visiongain.com

Contents

11. Qualitative Analysis of the Dermatological Drugs Market 2014-2024

11.1 SWOT Analysis of the Dermatological Drugs Market

11.2 Strengths

11.2.1 A Strong R&D Pipeline

11.2.2 High Unmet Clinical Need

11.2.3 Strong Industry-Physician Relationships

11.3 Weaknesses

11.3.1 Patient Adherence to Treatment

11.3.2 Limited Efficacy and Adverse Effects

11.3.3 Patent Expiry and Generic Competition

11.4 Opportunities

11.4.1 Growth Areas: Skin Infections, Onychomycosis and Melanoma

11.4.2 Consolidation in the Dermatology Market?

11.4.3 Personalised Dermatology: Technological Advances in Genomics

11.4.4 Advances in Topical Drug Delivery Methods

11.5 Threats

11.5.1 Increasing R&D Costs

11.5.2 Uncertain Reimbursement

11.5.3 Downward Pressures on Drug Prices

11.6 Porter’s Five Forces Analysis of the Dermatological Drugs Market

11.6.1 Rivalry Among Competitors [Medium]

11.6.2 Threat of New Entrants [High]

11.6.3 Power of Suppliers [Low]

11.6.4 Power of Buyers [Medium]

11. Qualitative Analysis of the Dermatological Drugs Market 2014-

www.visiongain.com

Contents

11.6.5 Threat of Substitutes [Medium]

12. Research Interviews

12.1 Interview with Mr Peter R. Culpepper, CFO/COO, Provectus Biopharmaceuticals, Inc.,

Knoxville, Tennessee, USA

12.1.1 Provectus’ Pipeline: PV-10 and PH-10

12.1.2 The Dermatological Drugs Market

12.2 Interview with Dr. Mike Bastian, Business Development Manager, Birken AG, Niefern-

Öschelbronn, Germany

12.2.1 Birken’s Pipeline: Oleogel S-10

12.2.2 The Dermatological Drugs Market

12.3 Interview with Dr Steven Feldman, Director of the Phototherapy Treatment Center, Wake

Forest University School of Medicine, Winston-Salem, North Carolina, USA

12.3.1 Psoriasis: Unmet Patent Needs

12.3.2 Leading Dermatology Markets

12.3.3 Patient Adherence is Crucial

12.3.4 The Future of Biological Drug Treatments

12.3.5 Technological and Pipeline Developments

12.3.6 Challenges for Dermatologic Treatments

12.4 Interview with Professor Hermann Lübbert, PhD, Chief Executive Officer, Biofrontera AG,

Leverkusen, Germany

12.4.1 Current State of the Dermatological Drug Market

12.4.2 Biofrontera and Dermatologic Drugs

12.4.3 Future Prospects for the Dermatological Drug Market

12.4.4 High Medical Need in Inflammatory Skin Diseases and Skin Cancers

12. Research Interviews

www.visiongain.com

Contents

12.4.5 Challenges Facing the Dermatologic Drug Market

12.4.6 Thoughts on Biologics, Small Molecule and Combination Therapies

13. Conclusions

13.1 The World Dermatological Drugs Market in 2012 and 2013

13.1.1 Current Leading Dermatological Drugs Segments

13.1.2 Leading Dermatological Drugs Products

13.1.3 Leading Dermatological Drugs Companies

13.1.4 Leading National Markets

13.2 World Dermatological Drugs Market Forecast 2014-2024

13.3 The Future of the Dermatological Drugs Market?

13. Conclusions

www.visiongain.com Page 98

Dermatological Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies

Table 4.12 Spanish Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024

2012 2013 2014 2015 2016 2017 2018Spain ($m) 452 487 521 551 570 592 602 Annual Growth Rate (%) 7.9 7.1 5.6 3.5 3.9 1.6CAGR (%, 2012-2018) 4.9

2018 2019 2020 2021 2022 2023 2024Spain ($m) 602 617 633 647 666 682 695 Annual Growth Rate (%) 1.6 2.5 2.5 2.4 2.8 2.4 2.0CAGR (%, 2018-2024) 2.4CAGR (%, 2012-2024) 3.7

Figure 4.15 Spanish Dermatological Drugs Market Forecast: Revenues ($m), AGR (%), 2012-2024

Visiongain predicts that the Spanish market will grow with a CAGR of 4.9% over 2012-2018 to

reach $602m in 2018. As in other EU countries, growth in healthcare spending will be limited by

slow economic growth. In 2011, a fall in total spending was noted by the Spanish health ministry.

The market will be restrained by recent financial problems and laws introduced by the Spanish

government mean that the pharmaceutical market will be increasingly supplied with generic drugs;

therefore making a challenging R&D environment over the forecast period. However, the need for

new dermatologic drug treatments, such as those for treating skin cancer and skin and skin

0.0

1.0

2.0

3.0

4.0

5.0

6.0

7.0

8.0

9.0

0

100

200

300

400

500

600

700

800

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AGR

(%)

Sale

s ($

m)

Year Sales ($m) AGR (%)

Source: visiongain 2014

Source: visiongain 2014

www.visiongain.com Page 123

Dermatological Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies

The annual cost of treatment with Stelara is reportedly $18,200 for a low dose or $33,600 for a

high dose. This is apparently more expensive than $14,543 Enbrel and $16,978 Humira, reports

also indicate. The drug’s high revenue is affected by this high cost; in 2012, sales of Stelara

generated $1,025m.

5.8.1 Stelara: Sales Forecast 2014-2024

Table 5.7 and Figure 5.7 show visiongain’s estimates of Stelara revenues in psoriasis and psoriatic

arthritis over 2012-2024.

Table 5.7 Johnson & Johnson: Stelara Revenue ($m), AGR (%), CAGR (%), 2012-2024

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Stelara ($m) 1,025 1,504 1,835 2,055 2,240 2,419 2,540 2,667 2,774 2,829 2,914 2,943 1,913 Annual Growth Rate (%) 46.7 22.0 12.0 9.0 8.0 5.0 5.0 4.0 2.0 3.0 1.0 -35.0CAGR (%, 2012-2018 and 2018-2024)

16.3 -4.6

CAGR (%, 2012-2024) 5.3

Figure 5.7 Johnson & Johnson: Stelara Revenue ($m), AGR (%), 2012-2024

In 2012, Johnson & Johnson reported Stelara revenues of $1,025m, representing 16.9% of the

psoriasis drugs market. This increased in 2013 to $1,504m, up 46.7% on 2012. Growth was due to

-40.0-30.0-20.0-10.00.010.020.030.040.050.060.0

0

500

1,000

1,500

2,000

2,500

3,000

3,500

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AGR

(%)

Sale

s ($

m)

Year Sales ($m) AGR (%)

Source: visiongain 2014

Source: visiongain 2014

www.visiongain.com Page 200

Dermatological Drugs Market Forecast 2014-2024: Future Prospects for Leading Companies

The company reports revenues from its Dermatology business segment, which includes Bactroban

and Duac (and presumably Soriatane) but excludes Valtrex and Zovirax. GSK also markets drugs

for treating melanoma, notably Tafinlar and Mekinist, though these have not been considered part

of GSK’s dermatology revenues.

9.4.2 GSK: Sales Forecast 2014-2024

Table 9.8 and Figure 9.4 show visiongain’s estimates of GSK’s dermatological drugs revenues

over 2012-2024.

Table 9.8 GSK: Dermatological Drugs Revenue ($m), AGR (%), CAGR (%), 2012-2024

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024GSK ($m) 1,888 1,682 1,544 1,497 1,468 1,450 1,439 1,435 1,416 1,401 1,390 1,379 1,370 Annual Growth Rate (%) -10.9 -8.2 -3.0 -2.0 -1.2 -0.7 -0.3 -1.3 -1.0 -0.8 -0.7 -0.7CAGR (%, 2012-2018 and 2018-2024)

-4.4 -0.8

CAGR (%, 2012-2024) -2.6

Figure 9.4 GSK: Dermatological Drugs Revenue ($m), AGR (%), 2012-2024

Visiongain’s sales forecast for GSK includes GSK’s reported Dermatology revenues, as well as

sales of Valtrex and GSK’s share of sales of Zovirax. We estimate that in 2012, GSK's

-12.0

-10.0

-8.0

-6.0

-4.0

-2.0

0.0

0200400600800

1,0001,2001,4001,6001,8002,000

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

AGR

(%)

Sale

s ($

m)

Year Sales ($m) AGR (%)

Source: visiongain 2014

Source: visiongain 2014